Exploring Experimental Hematology: May 2025 (Volumes 143 & 145)
.png)
Read highlights of the following articles from Experimental Hematology, volumes 143 and 145. A distinct alternative mRNA splicing profile identifies the oncogenic CD44 transcript variant 3 in KMT2A-rearranged pediatric T-cell acute lymphoblastic leukemia cells. Ramilo Amor, Amanda et al. Experimental Hematology, Volume 145, 104712 The recent FDA approval of menin inhibitors targeting key genetic drivers of myeloid leukemia, such as KMT2A (lysine methyl transferase 2A) rearrangements and NPM1 mutations, has drawn attention to a recent article in press in Experimental Hematology. KMT2A rearrangement (KMT2A-r) is associated with a poorer prognosis in myeloid and lymphoid leukemia. The study is focused on the KMT2A rearrangement in T-ALL and how it is distinct from KMT2A-negative (KMT2A-wt) T-ALL. The authors performed transcriptome profiling on 171 primary T-ALL samples (n=161 wt vs n=10 KMT2A rearranged samples). They found that 15% of the genes were significantly differ...